Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cellares’ Cell Shuttle Receives FDA AMT Designation | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cellares’ Cell Shuttle Receives FDA AMT Designation

This acknowledges the Cell Shuttle’s ability to automate and reliably manufacture cell therapies.

By: Rachel Klemovitch

Assistant Editor

Cellares, an Integrated Development and Manufacturing Organization (IDMO), announced that its Cell Shuttle has received the Advanced Manufacturing Technology (AMT) designation by the FDA’s Center for Biologics Evaluation and Research (CBER). 

This designation acknowledges the Cell Shuttle’s ability to automate and reliably manufacture cell therapies and represents a significant step forward in the advanced manufacturing of cell therapies.

As a result of this designation, developers leveraging Cellares’ IDMO Manufacturing services will receive expedited FDA review, resulting in decreased times to IND and BLA, as well as a streamlined pathway to the approval of additional cell therapies leveraging the Cell Shuttle as a platform for their processes.

Cellares’ Cell Shuttle has performed automated, end-to-end, cell therapy manufacturing, including the processes of cell enrichment, cell selection, transduction, transfection, activation, expansion, and formulation while meeting all in-process and final product specifications of commercial cell therapies. 

Eric Fulmer, Vice President of Quality at Cellares. “By automating cell therapy manufacturing on the Cell Shuttle, our clients will have a streamlined and cost-effective pathway from clinical development to commercial manufacture, ultimately accelerating patient access to these critical therapies.”

With IDMO Smart Factories in development across the US, Europe, and Japan, Cellares offers clients global cell therapy manufacturing services to support early clinical development that also seamlessly scales to support industrial-scale manufacturing in the commercial setting, achieving economies of scale even at low production volumes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics